Shots:

• The BTD is based on early and preliminary clinical data involves assessing TAK-994 for the treatment of EDS that may demonstrated substantially improved objective and subjective measurements of daytime wakefulness in NT1 patients
• TAK-994 is being evaluated in an ongoing P-II TAK-994-1501 study while the completed data from study will be presented at a future scientific conference
• TAK-994 (PO) is an investigational orexin agonist. If approved- the therapy will provide a future treatment option targeting orexin 2 receptors underlying NT1

Ref: Businesswire | Image: Takeda